Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Launched by CSL BEHRING · Jul 18, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Received treatment with CSL222 in Study CSL222_2001 or Study CSL222_3001, and completed participation in Study CSL222_2001 or Study CSL222_3001 or at least 5 years have passed since receiving CSL222.
- Exclusion Criteria:
- • Not Applicable
About Csl Behring
CSL Behring is a global biotechnology leader focused on developing innovative therapies for patients with serious and rare diseases. As a subsidiary of CSL Limited, the company specializes in the research, development, and manufacture of life-saving biotherapies derived from human plasma. With a strong commitment to scientific excellence and patient care, CSL Behring conducts rigorous clinical trials to advance its portfolio of immunoglobulins, clotting factors, and other biopharmaceuticals. The organization aims to enhance the quality of life for patients worldwide while maintaining the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Brussels, , Belgium
Sacramento, California, United States
Phoenix, Arizona, United States
Ann Arbor, Michigan, United States
Los Angeles, California, United States
Leuven, , Belgium
Southampton, , United Kingdom
Los Angeles, California, United States
San Diego, California, United States
Sacramento, California, United States
Ann Arbor, Michigan, United States
Little Rock, Arkansas, United States
Amsterdam Zuidoost, , Netherlands
London, England, United Kingdom
Aurora, Colorado, United States
Chapel Hill, North Carolina, United States
Nashville, Tennessee, United States
Leuven, , Belgium
Copenhagen, , Denmark
Rotterdam, , Netherlands
Utrecht, , Netherlands
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Diego, California, United States
Tampa, Florida, United States
Ann Arbor, Michigan, United States
Salt Lake City, Utah, United States
Brussels, , Belgium
Leuven, , Belgium
Dublin, , Ireland
Amsterdam Zuidoost, , Netherlands
London, England, United Kingdom
Southampton, , United Kingdom
Seattle, Washington, United States
Berlin, , Germany
Dublin, , Ireland
Groningen, , Netherlands
Malmo, , Sweden
Southampton, , United Kingdom
Portland, Oregon, United States
Patients applied
Trial Officials
Study Director
Study Director
CSL Behring
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported